POLXF — Polydex Pharmaceuticals Share Price
Last trade - 00:00- $6.82m
- $6.03m
- $4.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.05 | ||
| Price to Tang. Book | 1.05 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.39 | ||
| EV to EBITDA | 16.48 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.1% | ||
| Return on Equity | -2.24% | ||
| Operating Margin | -2.94% | ||
Financial Summary
| Year End 31st Jan | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.62 | 5.28 | 4.94 | 5.14 | 4.86 | n/a | n/a | -4.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -47.9 | -32.33 | -48.3 | +31.52 | -29.81 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Polydex Pharmaceuticals Limited is a company, which is engaged in the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. The Company also manufactures bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry. It focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. The Company’s products include Iron Dextran and Dextran Sulphate. The Company sells Iron Dextran to independent distributors and wholesalers primarily in Europe, the Far East, South America and Canada. Iron Dextran is a derivative of Dextran produced by complexing iron with Dextran. Iron Dextran is injected into pigs at birth as a treatment for anemia. Dextran Sulphate manufactured by the Company is sold primarily to independent distributors, or direct to companies in the United States and Europe for analytical applications.
Directors
- George Usher CHM (62)
- David Jamestee CFO (55)
- Sharon Wardlaw COO (68)
- Derek Lederer DRC (79)
- Martin Lipper DRC (86)
- Last Annual
- January 31st, 2021
- Last Interim
- July 31st, 2021
- Incorporated
- June 14th, 1979
- Public Since
- February 6th, 1981
- No. of Employees
- 21
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 3,432,478
- Address
- 421 Comstock Rd, SCARBOROUGH, M1L 2H5
- Web
- https://www.polydex.com/
- Phone
- +1 4167552231
- Contact
- Linda C. Hughes
- Auditors
- Schwartz Levitsky Feldman
Upcoming Events for POLXF
Similar to POLXF
Acacia Diversified Holdings
Pink Sheets on Nasdaq
Acusphere
Pink Sheets on Nasdaq
Soul Biotechnology
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 01:18 UTC, shares in Polydex Pharmaceuticals are trading at $1.96. This share price information is delayed by 15 minutes.
Shares in Polydex Pharmaceuticals last closed at $1.96 and the price had moved by +120.22% over the past 365 days. In terms of relative price strength the Polydex Pharmaceuticals share price has outperformed the S&P500 Index by +92.77% over the past year.
There is no consensus recommendation for this security.
Polydex Pharmaceuticals does not currently pay a dividend.
Polydex Pharmaceuticals does not currently pay a dividend.
Polydex Pharmaceuticals does not currently pay a dividend.
To buy shares in Polydex Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.96, shares in Polydex Pharmaceuticals had a market capitalisation of $6.73m.
Here are the trading details for Polydex Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: POLXF
Based on an overall assessment of its quality, value and momentum Polydex Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Polydex Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +231.12%.
As of the last closing price of $1.96, shares in Polydex Pharmaceuticals were trading +74.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Polydex Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Polydex Pharmaceuticals' management team is headed by:
- George Usher - CHM
- David Jamestee - CFO
- Sharon Wardlaw - COO
- Derek Lederer - DRC
- Martin Lipper - DRC